Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer

INTRODUCTION: Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration‐resistant prostate cancer. CASE PRESENTATION: A 62‐year‐old patient with a bone metastatic castration‐resistant prostate cancer was started on abiraterone acetate at a dose of 1000 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanai, Yoshinori, Kosaka, Takeo, Hongo, Hiroshi, Oya, Mototsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292133/
https://www.ncbi.nlm.nih.gov/pubmed/32743408
http://dx.doi.org/10.1002/iju5.12073
Descripción
Sumario:INTRODUCTION: Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration‐resistant prostate cancer. CASE PRESENTATION: A 62‐year‐old patient with a bone metastatic castration‐resistant prostate cancer was started on abiraterone acetate at a dose of 1000 mg a day along with 10 mg prednisone. In spite of castrate testosterone level, the laboratory test showed a relatively high level of serum testosterone, which was 21 ng/dL. Within 6 months, the patient achieved a complete prostate‐specific antigen response. Follow‐up bone scintigraphy demonstrated no area of intense uptake. He had a history of hyperlipidemia and was started on atorvastatin at home just after starting abiraterone acetate. CONCLUSION: This report is a rare case of a clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer.

Ejemplares similares